Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Metastatic Breast Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT03975647
What this trial is testing

Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer 466
Testing effectiveness (Phase 2)Ended earlyNCT01702558
What this trial is testing

A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)

Who this might be right for
Breast CancerGastric Cancer
Hoffmann-La Roche 182
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07152782
What this trial is testing

T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis

Who this might be right for
Breast Cancer With Brain MetastasisHER2-positive Breast Cancer
Fudan University 202
Testing effectiveness (Phase 2)Looking for participantsNCT05573126
What this trial is testing

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Who this might be right for
Hormone Receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast Cancer
Ellipses Pharma 95
Early research (Phase 1)UnknownNCT05504213
What this trial is testing

A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 224
Testing effectiveness (Phase 2)Study completedNCT02954055
What this trial is testing

MEtronomic TrEatment Option in Advanced bReast cAncer

Who this might be right for
Breast Cancer
ETOP IBCSG Partners Foundation 140
Testing effectiveness (Phase 2)Study completedNCT00777101
What this trial is testing

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerBreast Cancer
Puma Biotechnology, Inc. 233
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07701941
What this trial is testing

Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor PositiveHER2-low or HER2-ultralowUnresectable or Metastatic Breast Cancer
Daiichi Sankyo 220
Testing effectiveness (Phase 2)Looking for participantsNCT07112053
What this trial is testing

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
University of Washington 40
Large-scale testing (Phase 3)Looking for participantsNCT06846437
What this trial is testing

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Who this might be right for
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
Shanghai JMT-Bio Inc. 228
Testing effectiveness (Phase 2)UnknownNCT04605575
What this trial is testing

Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast CancerPyrotinibBreast Diseases+2 more
Sun Yat-sen University 208
Large-scale testing (Phase 3)Looking for participantsNCT07673029
What this trial is testing

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
GeneQuantum Healthcare (Suzhou) Co., Ltd. 228
Testing effectiveness (Phase 2)Active Not RecruitingNCT03368729
What this trial is testing

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2 Positive Breast Carcinoma
University of Alabama at Birmingham 46
Not applicableStudy completedNCT06655545
What this trial is testing

18F-fluoroestradiol (18F-FES) PET/CT Guided First-line Treatment for HR+/HER2- Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer
Fudan University 473
Not applicableStudy completedNCT04276272
What this trial is testing

D4 Choline Breast PET/CT

Who this might be right for
HER2-negative Breast CancerER Positive Breast CancerMetastatic Breast Cancer
Imperial College London 6
Testing effectiveness (Phase 2)Study completedNCT04072952
What this trial is testing

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Arvinas Estrogen Receptor, Inc. 217
Testing effectiveness (Phase 2)Study completedNCT00885755
What this trial is testing

Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 33
Testing effectiveness (Phase 2)Active Not RecruitingNCT03304080
What this trial is testing

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

Who this might be right for
Breast NeoplasmsBreast Diseases
Icahn School of Medicine at Mount Sinai 44
Early research (Phase 1)Active Not RecruitingNCT04704661
What this trial is testing

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Who this might be right for
Advanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more
National Cancer Institute (NCI) 51
Large-scale testing (Phase 3)Ended earlyNCT01303679
What this trial is testing

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Who this might be right for
First Line Metastatic Breast Cancer
ARCAGY/ GINECO GROUP 117
Next Page